Literature DB >> 7854062

Peptide YY derivatives as selective neuropeptide Y/peptide YY Y1 and Y2 agonists devoided of activity for the Y3 receptor sub-type.

Y Dumont1, A Cadieux, L H Pheng, A Fournier, S St-Pierre, R Quirion.   

Abstract

Peptide YY derivatives were evaluated for their respective ability to bind and activate the NPY/PYY receptor sub-types (Y1, Y2 and Y3) present in various preparations. The analogue [Leu31,Pro34]PYY demonstrated high (nM) affinity in rat frontoparietal cortical membrane preparations (Y1-enriched tissue) and the rabbit saphenous vein (Y1 in vitro bioassay) but only low affinity in a Y2-enriched preparation (rat hippocampus). In contrast, PYY C-terminal fragments such as PYY3-36 and PYY13-36 were more potent in Y2 than Y1 assays. Interestingly, and in contrast to [Leu31,Pro34]NPY and NPY13-36, the PYY derivatives [Leu31,Pro34]PYY and PYY3-36 were inactive in a purported Y3 bioassay (rat colon). These results suggest that [Leu31,Pro34]PYY and PYY3-36 respectively represent the first selective and potent Y1 and Y2 agonists, devoided of significant affinity/activity for the Y3 receptor class.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7854062     DOI: 10.1016/0169-328x(94)90105-8

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  8 in total

1.  BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist.

Authors:  Y Dumont; A Cadieux; H Doods; L H Pheng; R Abounader; E Hamel; D Jacques; D Regoli; R Quirion
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

2.  Peptide analogue studies of the hypothalamic neuropeptide Y receptor mediating pituitary adrenocorticotrophic hormone release.

Authors:  C J Small; D G Morgan; K Meeran; M M Heath; I Gunn; C M Edwards; J Gardiner; G M Taylor; J D Hurley; M Rossi; A P Goldstone; D O'Shea; D M Smith; M A Ghatei; S R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

3.  Administration of the Y2 receptor agonist PYY3-36 in mice induces multiple behavioral changes relevant to schizophrenia.

Authors:  Ulrike Stadlbauer; Wolfgang Langhans; Urs Meyer
Journal:  Neuropsychopharmacology       Date:  2013-06-10       Impact factor: 7.853

Review 4.  PET Imaging of the Neuropeptide Y System: A Systematic Review.

Authors:  Inês C F Fonseca; Miguel Castelo-Branco; Cláudia Cavadas; Antero J Abrunhosa
Journal:  Molecules       Date:  2022-06-09       Impact factor: 4.927

5.  Peripheral peptide YY inhibits propulsive colonic motor function through Y2 receptor in conscious mice.

Authors:  Lixin Wang; Guillaume Gourcerol; Pu-Qing Yuan; S Vincent Wu; Mulugeta Million; Muriel Larauche; Yvette Taché
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-11-05       Impact factor: 4.052

6.  Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226.

Authors:  R Abounader; J G Villemure; E Hamel
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

7.  Reversal by NPY, PYY and 3-36 molecular forms of NPY and PYY of intracisternal CRF-induced inhibition of gastric acid secretion in rats.

Authors:  M Gué; J L Junien; J R Reeve; J Rivier; D Grandt; Y Taché
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

Review 8.  The molecular signaling of exercise and obesity in the microbiota-gut-brain axis.

Authors:  Filipe M Ribeiro; Maycon A Silva; Victória Lyssa; Gabriel Marques; Henny K Lima; Octavio L Franco; Bernardo Petriz
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-28       Impact factor: 6.055

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.